1
Clinical Trials associated with GSK-2654911AAn Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of different formulations of a two-dose primary series and booster vaccination of monovalent Influenza H9N2 vaccine manufactured in Quebec, Canada with and without adjuvant, in adults 18 to 64 years of age.
100 Clinical Results associated with GSK-2654911A
100 Translational Medicine associated with GSK-2654911A
100 Patents (Medical) associated with GSK-2654911A
100 Deals associated with GSK-2654911A